Related Experiment Video
Updated: Jan 20, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
Current landscape for chimeric antigen receptor T cells in lymphomas
1Lymphoproliferative Disorders Program, Novant Health, Charlotte, North Carolina, USA.
Purpose Of Review:
CART cell therapy has changed the treatment landscape for relapsed/refractory aggressive lymphomas. In this article, we review the CART constructs most studied in lymphoma and their applicability.
Recent Findings:
Results of ZUMA-1, JULIET and TRANSCEND trials will be reviewed. Real-world data will also be reviewed.
Summary:
CART cell therapy is evolving and becoming safer. Increased uptake of this modality outside of clinical trials is expected.
Related Concept Videos
10:29Generation of Human Chimeric Antigen Receptor Regulatory T Cells
04:38An Ex Vivo Technique to Manufacture Chimeric Antigen Receptor T Cells
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
04:42An Ex Vivo Technique to Generate Tumor-Specific Chimeric Antigen Receptor T Cells
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
06:51Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

